{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:59:23Z","timestamp":1771001963650,"version":"3.50.1"},"reference-count":14,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To assess clinical outcomes and scintigraphic findings in horses with a bone fragility disorder (BFD) treated with zoledronate (a nitrogen-containing bisphosphonate).<\/jats:p>\n<jats:p><jats:bold>Design<\/jats:bold>\u2014Prospective uncontrolled clinical trial.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201410 horses with evidence of a BFD.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Signalment, history, and geographic location of horses' home environments were recorded. Physical examinations, lameness evaluations, and nuclear scintigraphy were performed. Diagnosis of a BFD was made on the basis of results of clinical and scintigraphic examination. Each horse was treated with zoledronate (0.075 mg\/kg [0.034 mg\/lb, IV, once]) at the time of diagnosis. Horses were reevaluated 6 months after treatment.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Affected horses were from the central and coastal regions of California and had \u2265 1 clinical sign of the disorder; these included scapular deformation (n = 2), lordosis (1), nonspecific signs of musculoskeletal pain (1), and lameness that could not be localized to a specific anatomic region (9). All horses had multiple sites of increased radiopharmaceutica uptake during initial scintigraphic evaluation of the axial skeleton and bones of 1 or both forelimbs. Six months after treatment, clinical improvement (defined as improvement in the lameness score, resolution of signs of musculoskeletal pain, or both) was detected in 9 of 10 horses; scintigraphic uptake was unchanged (n = 2) or subjectively decreased (8). No adverse effects attributed to zoledronate treatment were detected.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Treatment with zoledronate appeared to be useful in improving clinical outcome and scintigraphic findings in horses with a BFD; however, future placebo-controlled studies are necessary to accurately determine efficacy and long-term safety.<\/jats:p>","DOI":"10.2460\/javma.240.11.1323","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T14:23:46Z","timestamp":1337351026000},"page":"1323-1328","source":"Crossref","is-referenced-by-count":22,"title":["Use of zoledronate for treatment of a bone fragility disorder in horses"],"prefix":"10.2460","volume":"240","author":[{"given":"Scott A.","family":"Katzman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda M.","family":"Arens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda H.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Puchalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry D.","family":"Galuppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin J. W.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Am Vet Med Assoc","first-page":"1694","article-title":"Clinical and scintigraphic findings in horses with a bone fragility disorder: 16 cases (1980\u20132006)","volume":"232","author":"Anderson","year":"2008"},{"key":"ref2","series-title":"Current therapy in equine medicine","first-page":"303","article-title":"Silicosis and osteoporosis sydrome","author":"Durham","year":"2007"},{"key":"ref3","series-title":"Fractures and bone deformities in 18 horses with silicosis","first-page":"311","author":"Durham","year":"2006"},{"key":"ref4","series-title":"Vet Pathol","first-page":"593","article-title":"Osteoporosis associated with pulmonary silicosis in an equine bone fragility syndrome","volume":"48","author":"Arens","year":"2011"},{"key":"ref5","series-title":"Ann N Y Acad Sci","first-page":"209","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007"},{"key":"ref6","series-title":"J Bone Miner Res","first-page":"581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998"},{"key":"ref7","series-title":"N Engl J Med","first-page":"1809","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007"},{"key":"ref8","series-title":"N Engl J Med","first-page":"898","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005"},{"key":"ref9","series-title":"Guide for veterinary service and judging of equestrian events","year":"1991"},{"key":"ref10","series-title":"J Support Oncol","first-page":"475","article-title":"Adverse effects of bisphosphonates: current issues","volume":"5","author":"Diel","year":"2007"},{"key":"ref11","series-title":"Equine Vet J","first-page":"46","article-title":"Osteoporosis in a six year old pony","volume":"7","author":"Brook","year":"1975"},{"key":"ref12","series-title":"Arthritis Rheum","first-page":"2201","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001"},{"key":"ref13","series-title":"J Bone Miner Res","first-page":"1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997"},{"key":"ref14","series-title":"J Equine Vet Sci","first-page":"209","article-title":"A review of the efficacy of tiludronate in the horse","volume":"28","author":"Kamm","year":"2008"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/240\/11\/javma.240.11.1323.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/240\/11\/javma.240.11.1323.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/240\/11\/javma.240.11.1323.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:12:22Z","timestamp":1741353142000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/240\/11\/javma.240.11.1323.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":14,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.240.11.1323","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}